Figure 5.
PLSS and PASI scores over time in patients with psoriasis. (a) Observed mean (±SE) change from baseline* in PLSS and PASI following administration of GSK2831781 or placebo to patients with psoriasis. (b) Illustrative photograph of one participant showing a response following a GSK2831781 1.5 mg/kg. *No assessment at day 85 for 0.5 mg/kg treatment group. PASI, Psoriasis Activity Severity Index; PLSS, Psoriasis Lesion Severity Score.